JP4656859B2 - 酸化ストレス抑制剤 - Google Patents
酸化ストレス抑制剤 Download PDFInfo
- Publication number
- JP4656859B2 JP4656859B2 JP2004149334A JP2004149334A JP4656859B2 JP 4656859 B2 JP4656859 B2 JP 4656859B2 JP 2004149334 A JP2004149334 A JP 2004149334A JP 2004149334 A JP2004149334 A JP 2004149334A JP 4656859 B2 JP4656859 B2 JP 4656859B2
- Authority
- JP
- Japan
- Prior art keywords
- oxidative stress
- days
- uridylic acid
- age
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000036542 oxidative stress Effects 0.000 title claims description 30
- 239000003112 inhibitor Substances 0.000 title claims description 24
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 claims description 28
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 claims description 28
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 claims description 27
- 239000004480 active ingredient Substances 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 239000003623 enhancer Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 244000309466 calf Species 0.000 description 38
- 235000013305 food Nutrition 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 235000013336 milk Nutrition 0.000 description 14
- 239000008267 milk Substances 0.000 description 14
- 210000004080 milk Anatomy 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 230000035882 stress Effects 0.000 description 13
- 102000019197 Superoxide Dismutase Human genes 0.000 description 12
- 108010012715 Superoxide dismutase Proteins 0.000 description 12
- -1 lipid peroxide Chemical class 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 210000003022 colostrum Anatomy 0.000 description 11
- 235000021277 colostrum Nutrition 0.000 description 11
- 230000003308 immunostimulating effect Effects 0.000 description 11
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 235000013384 milk substitute Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000001629 suppression Effects 0.000 description 9
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 230000007815 allergy Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000036737 immune function Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 4
- 229940045145 uridine Drugs 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 208000016286 Iron metabolism disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
「バイオテクノロジー事典」(株)シー エム シー、1986年、10月9日、第246〜247頁
さらに、ウリジル酸が腸管免疫系に与える影響を検討した結果、ウリジンが腸管のIgA産生を高めることを見いだした。また、このとき、末梢血リンパ細胞のIFN−
γ産生が上昇することもはじめて見出した。
以下、本発明について詳述する。
ホルスタイン種新生仔ウシ(12頭)に対し、出生直後に各母ウシの初乳を給与し続く3日齢までIgGを強化した人工初乳を与えた。4日齢より仔ウシを2群に分け、10日齢に達するまでの7日間試験区(6頭)にウリジル酸入り代用乳(ウリジル酸 2g/日)を対照区(6頭)に通常の代用乳を給与した。その後、仔ウシを屠殺し、回腸粘膜を採取、液体窒素で凍結させIgA分析サンプルとした。
ホルスタイン種新生仔ウシ(12頭)に対し、出生直後に各母ウシの初乳を給与し続く3日齢までIgGを強化した人工初乳を与えた。4日齢より仔ウシを2群に分け、10日齢に達するまでの7日間試験区(6頭)にウリジル酸入り代用乳(ウリジル酸2g/日)を、対照区(6頭)に通常の代用乳を給与し、以後、24日齢まで試験区、対照区とも通常の代用乳を給与した。
ホルスタイン種新生仔ウシ(12頭)に対し、出生直後に各母ウシの初乳を給与し続く3日齢までIgGを強化した人工初乳を与えた。4日齢より仔ウシを2群に分け、10日齢に達するまでの7日間試験区(6頭)にウリジル酸入り代用乳(ウリジル酸2g/日)を、対照区(6頭)に通常の代用乳を給与した。
Claims (4)
- ウリジル酸のみを有効成分としてなること、を特徴とする酸化ストレス抑制剤。
- SOD活性増強によること、を特徴とする請求項1に記載の酸化ストレス抑制剤。
- ウリジル酸のみを有効成分としてなること、を特徴とするSOD活性増強剤。
- ウリジル酸のみを有効成分としてなる酸化ストレス抑制剤をヒトを除く動物に投与すること、を特徴とするヒトを除く動物の酸化ストレス抑制方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004149334A JP4656859B2 (ja) | 2004-05-19 | 2004-05-19 | 酸化ストレス抑制剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004149334A JP4656859B2 (ja) | 2004-05-19 | 2004-05-19 | 酸化ストレス抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005330213A JP2005330213A (ja) | 2005-12-02 |
JP4656859B2 true JP4656859B2 (ja) | 2011-03-23 |
Family
ID=35485116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004149334A Expired - Lifetime JP4656859B2 (ja) | 2004-05-19 | 2004-05-19 | 酸化ストレス抑制剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4656859B2 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4982041B2 (ja) * | 2004-07-01 | 2012-07-25 | 明治飼糧株式会社 | 家畜の筋肉内脂肪(サシ)増加方法及び剤 |
JP4482493B2 (ja) * | 2005-06-29 | 2010-06-16 | 明治飼糧株式会社 | ロタウイルス感染・増殖抑制剤 |
WO2007108071A1 (ja) * | 2006-03-17 | 2007-09-27 | Pharma Foods International Co., Ltd. | 抗ストレス組成物及びそれを含有する飲食品 |
EP2033647A4 (en) | 2006-06-27 | 2010-07-28 | Yamasa Corp | AGENT AGAINST PSYCHOSOCIAL CONSTRAINTS |
JP2008069126A (ja) * | 2006-09-15 | 2008-03-27 | Meiji Shiryo Kk | 脂肪細胞分化・脂質蓄積調節剤 |
JP4778946B2 (ja) * | 2007-12-03 | 2011-09-21 | 明治飼糧株式会社 | 血中尿酸値低下剤 |
JP5408882B2 (ja) * | 2008-01-23 | 2014-02-05 | ヤマサ醤油株式会社 | 唾液分泌促進剤 |
JP5426918B2 (ja) * | 2009-04-20 | 2014-02-26 | 株式会社 伊藤園 | ウリジンを含有する抗疲労剤又は体力向上剤 |
WO2014129996A1 (en) | 2013-02-21 | 2014-08-28 | Uludağ Üni̇versi̇tesi̇ Teknoloji̇ Transfer Ofi̇si̇ Ti̇caret Ve Sanayi̇ Anoni̇m Şi̇rketi̇ | Use of pyrimidines in stimulation of plant growth and development and enhancement of stress tolerance |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02500372A (ja) * | 1987-10-28 | 1990-02-08 | プロ‐ニューロン,インコーポレーテッド | アシル化ウリジンおよびシチジンならびにその使用 |
JPH10175866A (ja) * | 1996-12-18 | 1998-06-30 | Showa Denko Kk | 動物用ストレス反応緩和剤及びストレス反応の緩和方法 |
JPH11514973A (ja) * | 1995-09-05 | 1999-12-21 | テトラ・ベルケ・デーエル・エルエーエル・エヌアーテー・ウルリヒ・ベンシュ・ゲーエムベーハー | 水生動物の抗ストレス剤 |
JP2001314172A (ja) * | 1999-09-20 | 2001-11-13 | Meiji Milk Prod Co Ltd | 免疫賦活化組成物 |
-
2004
- 2004-05-19 JP JP2004149334A patent/JP4656859B2/ja not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02500372A (ja) * | 1987-10-28 | 1990-02-08 | プロ‐ニューロン,インコーポレーテッド | アシル化ウリジンおよびシチジンならびにその使用 |
JPH11514973A (ja) * | 1995-09-05 | 1999-12-21 | テトラ・ベルケ・デーエル・エルエーエル・エヌアーテー・ウルリヒ・ベンシュ・ゲーエムベーハー | 水生動物の抗ストレス剤 |
JPH10175866A (ja) * | 1996-12-18 | 1998-06-30 | Showa Denko Kk | 動物用ストレス反応緩和剤及びストレス反応の緩和方法 |
JP2001314172A (ja) * | 1999-09-20 | 2001-11-13 | Meiji Milk Prod Co Ltd | 免疫賦活化組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP2005330213A (ja) | 2005-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002311871B2 (en) | Compositions for treating animal diseases and syndromes | |
JP5191955B2 (ja) | 粘膜免疫調節剤並びにその用途 | |
Chirase et al. | Dietary zinc and manganese sources administered from the fetal stage onwards affect immune response of transit stressed and virus infected offspring steer calves | |
JP2001151675A (ja) | コクシジウム症の予防および/または治療用飼料 | |
JP4656859B2 (ja) | 酸化ストレス抑制剤 | |
EP1378236B1 (en) | Agents against stress-induced diseases | |
JP5584124B2 (ja) | 抗コクシジウム組成物 | |
JP2009102292A (ja) | ストレス抑制剤 | |
JP2022155522A (ja) | 免疫機能低下抑制剤及び免疫機能の低下抑制方法 | |
JP2008056628A (ja) | 睡眠誘導剤、ストレス性不眠症改善剤 | |
Ahfeethah et al. | Effect of humic acid and probiotics on immunity of broiler chickens | |
JP5140584B2 (ja) | 抗心理社会的ストレス剤 | |
JP4482493B2 (ja) | ロタウイルス感染・増殖抑制剤 | |
Dharmayudha et al. | Soil worms (Lumbricus rubellus) as feed additives for piglets' growth, blood profile and immunomodulators | |
Young | Yeast cell wall supplementation alters the performance and health of newly received crossbred heifers | |
US20040197342A1 (en) | Immunostimulator for animals and humans, and method of preventing animal and human infectious diseases and cancer | |
JPH0748274A (ja) | 養殖漁業における病原微生物感染症の予防並びに治療用飼料の製法 | |
Bryan | The effect of supplemental probiotics and spray-dried egg proteins on piglet growth performance characteristics | |
WO2019146652A1 (ja) | 抗i型アレルギー剤、及び肥満細胞又は好塩基球の脱顆粒抑制剤、並びに抗認知症剤、及び短期記憶障害改善/抑制剤 | |
JP2021193979A (ja) | 家畜の初乳品質改善剤及び方法 | |
Lonkar et al. | Effect of polyherbal liver stimulant (GenoLiv) on production performance, carcass characteristics, serum biochemistry and immune response in commercial broiler chickens. | |
Elakkad et al. | EFFECT OF LEVAMISOLE AND INMUNAIR17. 5® ON PERFORMANCE OF GROWING RABBITS | |
RU2538619C1 (ru) | Препарат для профилактики желудочно-кишечных болезней телят с синдромом диареи | |
JP5110683B2 (ja) | 睡眠誘導剤、ストレス性不眠症改善剤 | |
RU2370262C1 (ru) | Препарат для лечения и профилактики болезней, связанных с дефицитом селена для сельскохозяйственных животных |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070306 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070306 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100907 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101019 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101214 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101221 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140107 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4656859 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |